uniQure is delivering on the promise of gene therapy – single treatments with potentially curative results. The recent approvals of our gene therapy for hemophilia B – an historic achievement based on more than a decade of research and clinical development – represents a major milestone in the field of genomic medicine and ushers in a new treatment approach for patients living with hemophilia. We are now leveraging our modular and validated technology platform to advance a pipeline of proprietary gene therapies for the treatment of patients with Huntington’s disease, refractory temporal lobe epilepsy, ALS, Fabry disease, and other severe diseases. www.uniQure.com
The Innovation Awards were presented for the 16th time at NEMO Science Museum, to Zeliha Guler, Pepijn van Rutten and Olivier Lugier.
NewsFor the 16th time, the Amsterdam Science & Innovation Awards have taken place at NEMO Science Museum! It was a dazzling event in which 9 finalists took the stage to pitch their innovative ideas. An expert jury awarded three winners, Zeliha Guler (Amsterdam UMC), Pepijn van Rutten (VU) and Olivier Lugier (UvA) with an Innovation […]
NewsOnderzoekers Guus van Dongen, Dick den Hertog en Toby Kiers krijgen de Impact Award 2023. Deze wordt uitgereikt aan gerenommeerde onderzoekers die een betekenisvolle bijdrage leveren aan de maatschappij. Er zijn drie categorieën: Gezondheid, Maatschappij en Milieu & Klimaat. Categorie Gezondheid: Guus van Dongen, hoogleraar medische beeldvorming en biomarkers bij Amsterdam UMC, ontwikkelde nieuwe beeldvormende […]
News